Naslov
ONCOLOGY PHARMACIST AND RATIONALIZATION OF RESOURCES IN HOSPITAL

Autori
Javor, Eugen

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Libri Oncologici : Croatian Journal of Oncology , Vol. 50 No. Supplement 2, 2022. / Milas, Ivan - Zagreb : Klinički bolnički centar Sestre milosrdnice, 2022, 16-16

Skup
1st Croatian Virtual Congress of Oncology Pharmacy

Mjesto i datum
Zagreb, Hrvatska, 07.10.2021. - 10.10.2021

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Domaća recenzija

Ključne riječi
oncology pharmacist ; rationalisation of resources ; cost benefit

Sažetak
Introduction: Current trends in healthcare expenditures suggest an increase at alarmingly high rates. Many EU Member States recorded overall increases of expenses for more than 20 %: Romania, Estonia, Lithuania, Bulgaria, Luxembourg, Germany, Portugal, Austria, Hungary, Latvia, Malta, Czechia, Poland and Croatia between 2012 (for some states 2013 or 2014 have been used for comparison) and 2018. The pharmaceutical expenditure accounts roughly for one- quarter of all healthcare expenditure, and it is a significant driver of rising healthcare cost. In Croatia average increase in expenditure for medicines from 2015 to 2019 was 9.8% annually. Even more worrisome is the increase in expenses of 15.5% in 2019 compared with 2018. Oncology pharmacists are still insufficiently recognized healthcare professionals in Croatian healthcare system. Therefore, we have presented its economic value in rationalization of resources for medicines. Methods: We have searched through scientific and professional literature for pharmacoeconomic analyses describing economic impact, rationalization of resources, oncology pharmacist and clinical pharmacist. We have used our own data regarding pharmaceeconomic analysis of the involvement of clinical pharmacist in the hospital medicines policy in a rural area. Results: Oncology pharmacist is recognized in the European cancer organization (ECO) and involved as a team member in designing the Essential Requirements for Quality Cancer Care guidelines. Oncology pharmacist services are cost beneficial. The involvement of a clinical pharmacist in the hospital medicines policy in a rural area hospital results with an optimisation of investment in medicines and leads to substantial cost savings for the healthcare system. Conclusion: As a part of the multidisciplinary team an oncology pharmacist can make a significant contribution to rationalization of resources for medicines. Released resources can be used for further investment in medical profession and healthcare quality for oncology patients. Oncology pharmacist is still an underutilized healthcare professional, expert for drugs, in the Croatian healthcare system. Through our joint work we can achieve a better positioning of the oncology pharmacist in the care of oncology patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA